Cargando…

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model

Long-acting antiretroviral agents for preexposure prophylaxis (PrEP) represent a promising new alternative to daily oral regimens for HIV prevention. Lenacapavir (LEN) is a first-in-class long-acting capsid inhibitor approved for the treatment of HIV-1 infection. Here, we assessed the efficacy of LE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bekerman, Elena, Yant, Stephen R., VanderVeen, Laurie, Hansen, Derek, Lu, Bing, Rowe, William, Wang, Kelly, Callebaut, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425210/ https://www.ncbi.nlm.nih.gov/pubmed/37384413 http://dx.doi.org/10.1172/JCI167818

Ejemplares similares

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks
por: VanderVeen, Laurie, et al.
Publicado: (2021)

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
por: Vidal, Samuel J., et al.
Publicado: (2021)

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
por: Swanstrom, Adrienne E., et al.
Publicado: (2023)

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection
por: Bekerman, Elena, et al.
Publicado: (2020)

Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir
por: García-Lerma, J. Gerardo, et al.
Publicado: (2008)

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
por: Cilento, Maria E., et al.
Publicado: (2022)

Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection
por: Young, Isabella C., et al.
Publicado: (2023)

Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
por: Radzio-Basu, Jessica, et al.
Publicado: (2019)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2022)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
por: Grinsztejn, Beatriz, et al.
Publicado: (2023)

The European preexposure prophylaxis revolution
por: Cairns, Gus, et al.
Publicado: (2016)

Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis
por: Zheng, Qi, et al.
Publicado: (2012)

Eligibility for HIV Preexposure Prophylaxis, Intention to Use Preexposure Prophylaxis, and Informal Use of Preexposure Prophylaxis Among Men Who Have Sex With Men in Amsterdam, the Netherlands
por: Hulstein, Sebastiaan H., et al.
Publicado: (2021)

Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
por: Walensky, Rochelle P., et al.
Publicado: (2016)

Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022)

Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)

The use of preexposure treatments for HIV prophylaxis
por: Majid, Adrian, et al.
Publicado: (2012)

Statistical issues in trials of preexposure prophylaxis
por: Dunn, David T., et al.
Publicado: (2016)

Epigallocatechin-3-gallate local pre-exposure application prevents SHIV rectal infection of macaques
por: Liu, JB, et al.
Publicado: (2018)

Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women
por: Anderson, Peter L., et al.
Publicado: (2016)

Oral preexposure prophylaxis continuation, measurement and reporting
por: Stankevitz, Kayla, et al.
Publicado: (2020)

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80
por: Kumar, Princy N, et al.
Publicado: (2023)

Women Trust Their OBGYNs to Provide Preexposure Prophylaxis: An Opportunity for HIV Prevention
por: Danvers, Antoinette A., et al.
Publicado: (2022)

Antimicrobial prophylaxis does not improve post-surgical outcomes in SIV/SHIV-uninfected or SIV/SHIV-infected macaques (Macaca mulatta and Macaca fascicularis) based on a retrospective analysis
por: Moats, Cassandra, et al.
Publicado: (2022)

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022)

1542. Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?
por: Lat, Allen K, et al.
Publicado: (2023)

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

P41 - Preexposure prophylaxis of infants’ food allergy
por: Denisova, Svetlana, et al.
Publicado: (2014)

Effect of 6-Month HIV Preexposure Prophylaxis Dispensing With Interim Self-testing on Preexposure Prophylaxis Continuation at 12 Months: A Randomized Noninferiority Trial
por: Ortblad, Katrina F., et al.
Publicado: (2023)

Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
por: Amico, K. Rivet, et al.
Publicado: (2014)

Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis
por: Grant, Robert M., et al.
Publicado: (2015)

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
por: Fonner, Virginia A., et al.
Publicado: (2016)

The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
por: Donnell, Deborah, et al.
Publicado: (2017)

Preexposure Prophylaxis for the Prevention of HIV Infection — 2014 Available Online
Publicado: (2014)

Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States
por: Aaron, Erika, et al.
Publicado: (2018)

HIV Preexposure Prophylaxis in the U.S. Military Services — 2014–2016
por: Blaylock, Jason M., et al.
Publicado: (2018)

Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19
por: Kulkarni, Chanda, et al.
Publicado: (2021)

Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada
por: Knox, David C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bemec5cejil9m9hnc3d6rdim3n